Adenovirus has intriguing potential as a gene delivery vector and also as a lytic agent for virotherapy of cancer. [1] [2] [3] Considerable resources are being deployed to enable systemic targeting of adenovirus from intravenous injection; however, promiscuous patterns of infection and poor blood compatibility 4 means that most therapeutic strategies currently require direct intratumoural (IT) injection. 5, 6 The clinical trials of Onyx-015 that showed best responses involved direct IT injection of the virus, and the product licences granted in China for treatment of head and neck cancer using Gendicine (a non-replicating adenovirus expressing P53, marketed by SiBiono GeneTech) and H101 (based on Onyx-015 and marketed by Shanghai Sunway Biotech) both use IT delivery. Clearly this route of administration can be useful for local delivery of adenovirus gene and virotherapy.
However, solid tumours are often characterised by elevated interstitial hydrostatic pressure and high levels of extracellular matrix that inhibit hydraulic conductivity. 7 Accordingly, while IT administration maximises initial delivery of vector into the tumour, it is possible that virus particles will be quickly lost from the tumour, either by drainage into the circulation or by fluid seepage back through the site of injection. The level of tumour cell infection is thought to be related to the dose of virus administered 8 and so it is likely that any decrease in the tumour-associated virus load will diminish therapeutic efficacy. In addition, drainage of virus into the systemic circulation can trigger the activation of complement and cytokine/chemokine cascades 9, 10 increasing the possibility of systemic toxicities. [11] [12] [13] [14] [15] Dissemination into the circulation following IT injection has already been reported in both animal studies and clinical trials. [16] [17] [18] For example Wang et al. (2006) 19 explored injecting 20 or 50 ml of adenovirus solution IT, using an infusion rate of 1.0 ml s
À1
. With all injectate volumes there was considerable hepatic transduction, particularly at higher virus doses, implying shedding of viable virus from the tumour into the circulation although virus particle kinetics were not measured directly. Sauthoff et al. 16 assessed the distribution of viable virus particles following IT injection in mice by measuring plaque forming units of tissue lysates in vitro. Virus shedding was shown 10 min post injection by the presence of infectious adenovirus in serum samples, although it represented less than 0.1% of the injected dose. Determination of plaque forming units does not detect non-infectious virions (for example, post infection, or defective viruses); however, and so probably provides an underestimate of the rate of virus dissemination from the tumour. Similarly DeWeese et al. 17 and Tong et al.
20
both used QPCR to measure viral genomes in the plasma of patients following IT injection of adenovirus, reporting the presence of 0.1 and 3.3% of the injected dose at 30 min, respectively. However, it is known that adenovirus in the human circulation is predominantly associated with blood cells rather than plasma, 4 and so both of these reports probably also underestimate the amount of adenovirus escaping from the tumour.
In this study we report experiments undertaken to characterise the distribution of type 5 adenovirus particles following IT injection into subcutaneous human breast cancer xenografts, including rates of transfer to the systemic circulation and seepage from the injection site. QPCR and reporter gene expression have been used to assess biodistribution, and particular attention has been paid to the influence of the volume of injectate on the efficiency of tumour-retention of adenovirus. Two human breast cancer xenograft models were used, selected for different biological properties and stromal composition. MDA-231 is of myoepithelial origin, with a high metastatic index (reflecting high expression of matrix metalloproteinase 7 and basement matrix turnover), significant vascularisation and VEGF-mediated high vascular permeability. In contrast, ZR75.1 is a typical luminal epithelial cell that grows as cohesive sheets, expressing E-cadherin, epithelial membrane antigen and human milk fat globulin 1 but not matrix metalloproteinase 7, vimentin or tenascin and with a low invasive capacity. 21 Knowledge of the factors that influence drainage of virus from these tumours, and how such factors may be controlled, could help enhance transduction and reduce toxicity, potentially improving therapeutic outcome. ), retention in the tumour was relatively poor with only 6 Â 10 9 virus genomes (40% of the injected dose) recovered from the tumour (Figure 1a , empty bar), with 2 Â 10 9 viral genomes (13% of the injected dose) recovered from the liver (Figure 1b, empty bar) . The combined recovery of genomes from the spleen, kidney, lungs, blood, heart and ovaries was just 0.2% of the injected dose (data not shown). Wang et al. showed that 50 ml IT injections into 5-8 mm mouse breast carcinomas, at a rate of 5 ml s À1 , often produced 'cracks' in the tumour, with injectate leaking rapidly to the periphery and then into the bloodstream. In our studies the 4 Â 20 ml injection protocol seems to promote similar rapid drainage from small MDA-231 tumours, but not noticeably from large tumours. Interestingly, blood samples isolated only 10 min post IT injection from animals bearing small tumours showed that a total of just 1 Â 10 8 viral genomes were present in the blood stream (data not shown). Since 2 Â 10 9 genomes are found in the liver after 30 min, presumably trafficking there via the bloodstream, this suggests very rapid clearance into the liver from the blood. Rapid hepatic accumulation is also a feature of systemically delivered adenovirus and is probably mainly a result of capture by Kupffer cells. 13, 22 Capture by phagocytes is thought to play a role in the 9 -virus particles; (d) a total dose of 1.5 Â 10 10 -virus particles was given using the protocol shown. For some experiments (right side of panels (a-c) and all of (d)), injection sites were sealed immediately post injection using 3M Vetbond tissue adhesive. The injection regimen using the adhesive was as follows: 4 Â (injection+30 s waiting time with needle inside tumour, then addition of 5 ml of adhesive on injection site + waiting time of 30 s to set). All animals in (d) had small tumours. QPCR reactions were performed as previously described by Green et al. 22 to quantify adenovirus fibre gene. *Po0.05; **Po0.01.
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Influence of volume of injectate on retention of virus particles within small MDA-231 tumours
To assess directly the influence of injectate volume on tumour retention of viruses, small MDA-231 tumours were injected with 1.5 Â 10 10 virus particles using three different regimens (10 ml single injection, or four injections of 20 or 50 ml), with all injection sites sealed with surgical adhesive. Figure 1d shows that the single injection of 10 ml gave efficient tumour retention (93% of the input virus). In contrast a series of four 20 ml injections into different tumour quadrants gave a significantly lower retention (Po0.05), with only 53% of virus recovered from tumours, while four 50 ml injections gave even less (45%) virus recovery. These data show that greater retention of particles within tumours can be achieved by using smaller volumes of injectate, and it may be that loss of virus from the tumour after IT injection is determined mainly by the relative volume of tumour and injectate.
Adenovirus seeps from the injection site of large MDA-231 tumours beyond 30 min
Biodistribution of viral genomes was also measured 24 h following IT injection. In treatment groups without occlusion of the injection site the number of genomes recovered from MDA-231 tumours fell between 30 min and 24 h, irrespective of tumour size (Table 1) . For small tumours this equated to a drop from 43 to 24% of the injected dose, and in large tumours a decrease from 96 to 77%. There are several possible explanations, for example the adenovirus might have degraded within the tumour, it could have been progressively shed from the injection site, or it might have drained from tumours into the circulation and subsequently been sequestered by the liver. The level of viral genomes recovered from the liver at 24 h was actually lower than the level after 30 min, irrespective of tumour size, showing the efficiency of adenovirus degradation in the liver. Indeed, this rapid hepatic degradation of adenovirus, probably mediated by Kupffer cells, 24 would most likely mask any uptake of virus shed from the tumour between 30 min and 24 h.
To assess whether loss of virus through the injection sites was important over this time frame, the same experiment was performed using surgical adhesive to Adenoviral genome copies were quantified by QPCR in both tumour and liver after 30 min and 24 h following IT injection. As described in the legend to Figure 1 , small and large MDA-231 tumours were injected with a total of 1.5 Â 10 10 particles of AdLuc (4 Â 20 ml injections) with or without occlusion of injection sites using 3 M Vetbond Tissue Adhesive. Tumours and livers were harvested, homogenised and QPCR analysed after 30 min or 24 h of AdLuc IT injection. (Table 1) , and in large tumours no loss of virus was observed during this period. This suggests that progressive retrograde seepage of virus from the injection site is significant for both small and large tumours, and in large tumours it may account for the major route of virus loss over the first 24 h. These data make a compelling case for the use of surgical adhesive to seal the injection sites in clinical trials using IT injection, even when retrograde seepage is not an obvious problem.
Transgene expression correlates better with number of virus genomes at lower virus doses Figure 2b ). This is compatible with the distribution data seen in Figure 1 , and indicates that virus disseminating from the tumour into the circulation is still infectious, reinforcing the case for judicious choice of injectate volume.
Luciferase expression levels in small tumours (5 Â 10 6 light units/tumour; Figure 2a) were very similar to those in large tumours (6 Â 10 6 light units/tumour), despite the observation that threefold more adenovirus particles were retained in the larger tumours. This might suggest that the injections could access only a limited number of cells, and these could be efficiently transduced with the smaller number of viruses, with excess viruses failing to mediate efficient infection. This possibility is supported by the observation that the use of surgical adhesive in small tumours gave no significant increase in luciferase expression, despite the demonstration (Figure 1a ) that this gives 2-fold greater virus retention. On the basis of these observations we hypothesised that individual IT injections of 1.5 Â 10 10 virus particles may not maximise efficiency of transgene expression, and accordingly subsequent experiments used smaller numbers of particles for individual injections. 3 ) and large (1 cm 3 ) MDA-231 s.c. tumours were injected with AdLuc (4 Â 20 ml injections containing a total of 1.5 Â 10 10 virus particles), with or without the occlusion of injected sites, as described in the legend to Figure 1 . In (c) animals bearing large MDA-231 tumours were injected IT with a total of 1 Â 10 8 virus particles, using the injection protocol shown. Tumours and livers were harvested and homogenised in reporter lysis buffer at 300 mg ml
À1
. Tissue homogenate (25 ml) was analysed using a luciferase assay system (Promega, Southampton, UK) and measured using a Wallac Victor 2 1420 multilabel counter that was set to dispense 50 ml of luciferin/well. 8 virus particles of AdLuc using different injection regimens and they were live-imaged for luciferase activity using an Ivis100 luminescence camera 24 h post injection. One hundred microlitre of potassium luciferin (15.8 mg ml À1 ) was injected intraperitoneally 5 min before imaging. Injection regimens included a single injection of 10 or 80 ml or four injections of 20 or 50 ml each. Ventral and lateral images from single representative animals receiving each treatment are shown.
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8 virus particles per IT injection (with all injection sites sealed) we assessed the influence of injection regime on transgene expression in tumour and liver. Under these conditions a single injection (10 ml volume) gave high levels of transgene expression in tumour, similar to the total levels achieved following four 20 ml injections into different tumour quadrants (Figure 2c) , suggesting no saturation of local infection at this concentration of viruses. Further increased injectate volumes (4 Â 50 ml volumes) gave a threefold decrease in tumour transduction accompanied by a 10-fold rise in hepatic transgene expression, apparently reflecting increased drainage into the circulation.
Distribution of transgene expression within MDA-231 tumours
An Ivis100 luminescence camera was used to assess the pattern of transgene expression within solid tumours ( Figure 3 ). Transgene expression from the individual injections was always localised to just one region of the tumour, close to the site of injection and the use of larger volumes of injectate (80 ml) failed to promote better spread of expression than smaller volumes (10 ml). In contrast, transgene expression following multiple injections (4 Â 20 or 4 Â 50 ml) is spread more widely through the tumour. Animals were imaged ventrally and laterally, to focus on liver and tumour expression respectively and the use of larger volumes of injectate (4 Â 50 ml) can be seen clearly to associate with transfer of infectious virus particles to the liver.
Comparison of MDA-231 and ZR75.1 tumours Similar studies were also undertaken using ZR75.1 breast carcinoma xenografts, which have quite different morphology. One important difference observed in vitro is that ZR75.1 takes up approximately threefold more adenovirus particles (determined by quantitative PCR) than MDA-231 under the same infection conditions, and approximately 10-fold higher levels of transgene expression are observed (Figures 4a and b) . Following IT injection (2 Â 40 ml injections, containing a total of 2 Â 10 9 virus particles/tumour) into small tumours, animals bearing MDA-231 tumours showed approximately equal levels of transgene expression in liver and tumour. (Figures 4c and d) . In contrast animals bearing ZR75.1 xenografts showed approximately 10-fold higher These data suggest that several factors can influence the IT retention of virus particles following direct injection, and the level and distribution of transduction that results. They also suggest significant differences in behaviour between different tumour types.
Following IT injection of MDA-231 tumours there was significant seepage from the injection site, and the use of small volumes of injectate minimised transfer into the bloodstream as well as retrograde seepage. In contrast ZR75.1 tumours showed less transfer of virus into the systemic circulation, and much higher levels of tumour transduction. This raises the possibility that the matrix of ZR75.1 tumours (and possibly other luminal type tumours) is less prone to 'cracking' than that of MDA-231 (myoepithelial) tumours, perhaps reflecting different vascularisation, 25, 26 and also that more efficient uptake of virus particles into cells within the tumour can act as a 'sink' for virus particles and decrease loss from the tumour.
IT injections in animal models are usually made slowly, to minimise retrograde flow, although we found here that retrograde seepage can continue beyond 30 min after injection. In the clinical setting it may be impossible to give injections sufficiently slowly, particularly when the injection is made remotely at breath-hold into relatively inaccessible sites, and there may be several situations where surgical adhesive could be used to minimise seepage of virus particles from the injection site.
Adenovirus particles trigger a capsid-dependent innate inflammatory response independent of virus gene expression or replication, 14, 27 well documented using intravascular delivery routes in mouse and non-human primate studies and also in clinical trials. 15, 23, [28] [29] [30] [31] Although IT injection of adenovirus vectors should reduce the overall likelihood of inflammatory responses, our data suggest that the use of larger volumes of injectate may give substantial dissemination of virus into the systemic circulation. This might account for the incidences of flu-like symptoms widely reported in clinical trials. 6, 17, 32, 33 While these side effects are generally tolerable using current treatment strategies, the number and volume of IT injections should be considered carefully to maximise efficacy and minimise unnecessary toxicities, particularly at higher doses.
